Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease
Non-exclusive license for Solid Biosciences’ proprietary, next-generation myotropic capsid, AAV-SLB101, to accelerate development of KNA-155 for dysferlinopathy SEATTLE–(BUSINESS WIRE)–Kinea Bio Inc., a biotechnology company dedicated to developing transformative genetic medicines, today announced two major achievements…